CD274 and neoplasm: Immune suppression in the tumor microenvironment through PD-1 or CTLA-4 occurs in various tumors, and immune checkpoint inhibitors (anti-PD-1, anti-PD-L1, or anti-CTLA-4) amplify antitumor T-cell response (37).